Last Updated on December 24, 2023 by The Health Master
The US Food and Drug Administration (USFDA) has given final approval to Alembic Pharma’s abbreviated new drug application (ANDA) for cyclophosphamide capsules, 25 mg, and 50 mg.
The approved ANDA is therapeutically equivalent to the Reference Listed Drug (RLD) product, Cyclophosphamide capsules, 25 mg and 50 mg of Hikma Pharma USA Inc, a statement from Alembic Pharma has notified.
Cyclophosphamide capsule is an alkylating drug indicated for the treatment of malignant disease and minimal change nephrotic syndrome in pediatric patients, the statement noted.
USFDA gives nod to market this generic Antibiotic Drug
USFDA gives tentative approval for Drospirenone tablets
USFDA approves Ketorolac Tromethamine injection
USFDA gives final approval for Sodium Phenylbutyrate tablets
USFDA gives approval for Glycopyrrolate injection
USFDA gives final approval for Mesalamine extended-release capsules
Largest Pharma cluster in World to be launched in Telangana
NLEM: Anti-diabetes drugs and patented antivirals to get cheaper
IPC set to harmonise 31 General Chapters & Excipient Monographs of IP
First EC meeting of DCOIWA held at pink city Jaipur
USFDA issues Form 483 with 3 Observations to Alkem
Injections for Diabetes, Cancer could become unnecessary soon
USFDA gives nod to market this generic Antibiotic Drug
USFDA issued OAI Status to Sun Pharma
Pharmacy Inspectors to be appointed soon
Latest Notifications regarding Pharmaceuticals
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
